OpenURL Connection Search

Select item for more details and to access through your institution.

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial.
Published in:
Journal of the International AIDS Society, 2022, v. 25, n. 6, p. 1, doi. 10.1002/jia2.25905
By:
- Avihingsanon, Anchalee;
- Hughes, Michael D.;
- Salata, Robert;
- Godfrey, Catherine;
- McCarthy, Caitlyn;
- Mugyenyi, Peter;
- Hogg, Evelyn;
- Gross, Robert;
- Cardoso, Sandra W.;
- Bukuru, Aggrey;
- Makanga, Mumbi;
- Badal‐aesen, Sharlaa;
- Mave, Vidya;
- Ndege, Beatrice Wangari;
- Fontain, Sandy Nerette;
- Samaneka, Wadzanai;
- Secours, Rode;
- Van Schalkwyk, Marije;
- Mngqibisa, Rosie;
- Mohapi, Lerato
Publication type:
Article
HIV-1 RNA testing of pooled dried blood spots is feasible to diagnose acute HIV infection in resource limited settings.
Published in:
Southern African Journal of Infectious Diseases, 2018, v. 33, n. 2, p. 50, doi. 10.1080/23120053.2017.1393247
By:
- Dowling, Wentzel;
- Veldsman, Kirsten;
- Grace Katusiime, Mary;
- Maritz, Jean;
- Bock, Peter;
- Meehan, Sue-Ann;
- Van Schalkwyk, Marije;
- Cotton, Mark F;
- Preiser, Wolfgang;
- Van Zyl, Gert U
Publication type:
Article
Clinical Experience With Severe Acute Respiratory Syndrome Coronavirus 2–Related Illness in Children: Hospital Experience in Cape Town, South Africa.
Published in:
Clinical Infectious Diseases, 2021, v. 72, n. 12, p. e938, doi. 10.1093/cid/ciaa1666
By:
- Zalm, Marieke M van der;
- Lishman, Juanita;
- Verhagen, Lilly M;
- Redfern, Andrew;
- Smit, Liezl;
- Barday, Mikhail;
- Ruttens, Dries;
- Costa, A'ishah da;
- Jaarsveld, Sandra van;
- Itana, Justina;
- Schrueder, Neshaad;
- Schalkwyk, Marije Van;
- Parker, Noor;
- Appel, Ilse;
- Fourie, Barend;
- Claassen, Mathilda;
- Workman, Jessica J;
- Goussard, Pierre;
- Zyl, Gert Van;
- Rabie, Helena
Publication type:
Article
Diverse Human Immunodeficiency Virus–1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings.
Published in:
Clinical Infectious Diseases, 2020, v. 71, n. 7, p. e170, doi. 10.1093/cid/ciz1116
By:
- Wallis, Carole L.;
- Hughes, Michael D.;
- Ritz, Justin;
- Viana, Raquel;
- Silva de Jesus, Carlos;
- Saravanan, Shanmugam;
- van Schalkwyk, Marije;
- Mngqibisa, Rosie;
- Salata, Robert;
- Mugyenyi, Peter;
- Hogg, Evelyn;
- Hovind, Laura;
- Wieclaw, Linda;
- Gross, Robert;
- Godfrey, Catherine;
- Collier, Ann C.;
- Grinsztejn, Beatriz;
- Mellors, John W.
Publication type:
Article
Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.
Published in:
2021
By:
- Fichtenbaum, Carl J;
- Ribaudo, Heather J;
- Leon-Cruz, Jorge;
- Overton, Edgar T;
- Zanni, Markella V;
- Malvestutto, Carlos D;
- Aberg, Judith A;
- Kileel, Emma M;
- Fitch, Kathleen V;
- Schalkwyk, Marije Van;
- Kumarasamy, Nagalingeswaran;
- Martinez, Esteban;
- Santos, Breno Riegel;
- Joseph, Yvetot;
- Lo, Janet;
- Siminski, Sue;
- Melbourne, Kathleen;
- Sponseller, Craig A;
- Desvigne-Nickens, Patrice;
- Bloomfield, Gerald S
Publication type:
journal article
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.
Published in:
2020
By:
- Fichtenbaum, Carl J;
- Ribaudo, Heather J;
- Leon-Cruz, Jorge;
- Overton, Edgar T;
- Zanni, Markella V;
- Malvestutto, Carlos D;
- Aberg, Judith A;
- Kileel, Emma M;
- Fitch, Kathleen V;
- Schalkwyk, Marije Van;
- Kumarasamy, Nagalingeswaran;
- Martinez, Esteban;
- Santos, Breno Riegel;
- Joseph, Yvetot;
- Lo, Janet;
- Siminski, Sue;
- Melbourne, Kathleen;
- Sponseller, Craig A;
- Desvigne-Nickens, Patrice;
- Bloomfield, Gerald S
Publication type:
journal article
Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial.
Published in:
2020
By:
- Neilan, Tomas G;
- Nguyen, Kim-Lien;
- Zaha, Vlad G;
- Chew, Kara W;
- Morrison, Leavitt;
- Ntusi, Ntobeko A B;
- Toribio, Mabel;
- Awadalla, Magid;
- Drobni, Zsofia D;
- Nelson, Michael D;
- Burdo, Tricia H;
- Schalkwyk, Marije Van;
- Sax, Paul E;
- Skiest, Daniel J;
- Tashima, Karen;
- Landovitz, Raphael J;
- Daar, Eric;
- Wurcel, Alysse G;
- Robbins, Gregory K;
- Bolan, Robert K
Publication type:
journal article

Found: 7

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial.

HIV-1 RNA testing of pooled dried blood spots is feasible to diagnose acute HIV infection in resource limited settings.

Clinical Experience With Severe Acute Respiratory Syndrome Coronavirus 2–Related Illness in Children: Hospital Experience in Cape Town, South Africa.

Diverse Human Immunodeficiency Virus–1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings.

Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.

Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial.